Sedentary behavior and physical inactivity have independent effects on obesity and related cardiometabolic diseases. Previous studies on genelifestyle interaction and obesity have focused mostly on the FTO gene and physical activity, whereas little attention has been paid to sedentary behavior as indicated by television (TV) watching. In 2 prospective cohorts with 7740 women and 4564 men, we calculated a genetic risk score based on 32 established body mass index-associated variants to capture the overall genetic susceptibility and to examine its interactions with leisure time TV watching and physical activity in relation to adiposity. Our results indicate that prolonged TV watching might accentuate the genetic predisposition to elevated adiposity, whereas greater leisure time physical activity might attenuate the genetic association. These findings suggest that deleterious effects of genetic factors could be modified by lifestyle factors and challenge the common lay perception of deterministic genetic predisposition to obesity. Our data provide new information in understanding the interplay between genes and environment and emphasize the important role of both increases in exercise levels and reductions in sedentary behaviors in public health efforts to prevent obesity and related cardiometabolic diseases, particularly in individuals who are more genetically predisposed to obesity. See p 1821.
Multiple Reaction Monitoring to Identify Site-Specific Troponin I Phosphorylated Residues in the Failing Human Heart
Phosphorylation of cardiac troponin I, a myofilament protein, regulates myocyte function. Using mass spectrometry, we established that human cardiac troponin I is more extensively phosphorylated than previously reported, with 14 modifiable amino acid residues located throughout its entire length. Six novel phosphorylated amino acid residues were identified in functionally important regions of cardiac troponin I. Furthermore, sensitive mass spectrometry-based assays were developed to simultaneously quantify the extent of phosphorylation of each modifiable residue in control and human failing myocardium. Along with the heart failure-related dephosphorylation of known protein kinase A-targeted sites, we found increased phosphorylation of protein kinase C sites and several of the newly identified sites found in the C terminus of cardiac troponin I. In a canine model of heart failure with dyssynchrony, these C-terminal sites were hyperphosphorylated, and this change shifted back toward normal with cardiac resynchronization. These findings suggest correlation of phosphorylation of cardiac troponin I with functional status and potential utility as a tissue biomarker and therapeutic target. See p 1828.
Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions
Dipeptidyl peptidase-4 (DPP4) is a serine protease with a primary function of truncating various bioactive molecules such as incretin hormones, angiogenic chemokines, inflammatory cytokines, denatured collagen, and brain natriuretic peptide. To date, the pathophysiological significance of DPP4 in the processes of diabetes mellitus, malignancy, and inflammation has been well recognized and well established; however, the role of DPP4 in the pathogenesis of cardiovascular disease remained unclear until as recently as several years ago, when the first report demonstrated the protective role of DPP4 inhibition in acute myocardial infarction. The present study highlights a novel pathophysiological role for DPP4 in diastolic left ventricular dysfunction and raises the possibility of using DPP4 as a diagnostic surrogate and a therapeutic target for chronic heart failure. One of the primary interpretations drawn from the present study is that the coronary microcirculation is essential for diastolic left ventricular dysfunction development, in which DPP4 may play a pathophysiological role by regulating coronary angiogenesis. Diabetes mellitus has been postulated to exacerbate heart failure, and the comorbidity of diabetic retinopathy, ie, diabetic microvasculopathy, has been suggested to be associated with the increased incidence of heart failure in patients with diabetes mellitus. Thus, the present study proposes another therapeutic benefit of the small-molecule DPP4 inhibitors in reducing the incidence of heart failure in patients with diabetes mellitus. See p 1838.
Trends in Blood Pressure and Hypertension Detection, Treatment, and Control 1980 to 2009: The Minnesota Heart Survey
Hypertension is common in the United States, afflicting more than 76 million adults aged Ն25 years. Treatment is well established, which reduces the cardiovascular complications of hypertension, particularly stroke. In a large metropolitan area, hypertension detection and control has been a goal for many years. The results of this sustained focus are shown in the present report, in which Ϸ70% of hypertensive subjects in the adult population were aware of their hypertension, were treated, and had their blood pressure controlled to recommended levels. This may in part be because of higher rates of insurance, education, and income in the state of Minnesota; however, it also points to quality healthcare systems that have targeted high blood pressure as an important goal for cardiovascular disease prevention. With this combination of factors, it is possible to have high levels of blood pressure control and resulting declines in stroke deaths. See p 1852.
Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus
Patients with diabetes mellitus are at increased risk of adverse cardiac events even in the absence of overt myocardial ischemia or scar compared with patients without diabetes mellitus. Coronary flow reserve (CFR) is a quantitative measure of coronary vascular dysfunction, which is an early manifestation of coronary artery disease. CFR can be measured noninvasively with positron emission tomography. The present study establishes that CFR is associated with increased rates of cardiac mortality among both diabetics and nondiabetics and results in similar improvement in risk discrimination and reclassification for both cohorts. In both cases, Ϸ1 in 3 patients has a clinically relevant change in assessed risk based on CFR, even after accounting for clinical risk factors and traditional stress imaging findings. Intriguingly, diabetic patients without known coronary artery disease with visually normal stress tests but impaired CFR experience a 2.8%/y cardiac mortality rate, comparable to that for patients with known coronary artery disease (2.0%/y). Conversely, diabetic patients without known coronary artery disease and visually normal stress tests who have preserved CFR experience cardiac mortality rates comparable to those of nondiabetic
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Original Research Put Into Perspective for the Practicing Clinician Volume 126 Ⅲ Number 15 Ⅲ October 9, 2012 patients free of coronary artery disease with normal stress imaging findings (0.3%/y versus 0.5%/y, respectively). These findings offer important insights into the mechanism of increased cardiac risk among diabetics and the classification of diabetes mellitus as a cardiac risk equivalent. See p 1858.
Cardiomyogenesis in the Aging and Failing Human Heart
For the last 70 years, the possibility that the adult heart retains after birth a significant capacity for myocyte regeneration has been opposed strongly. Similarly, the notion that stem cells reside within the myocardium and regulate tissue homeostasis physiologically and the repair process after injury has been challenged. Different approaches have provided contrasting results, which have divided the scientific community into supporters of an extremely low myocyte renewal in the mammalian heart and proponents of a relatively high myocyte replacement at all stages of life. Essentially, 2 opposite views are currently being purported: one that sees the heart as a static organ, characterized by a large number of myocytes that are present at birth and live as long as the organ and organism, and the other that considers the heart a highly dynamic organ in which the myocyte compartment is restored several times during the course of life. With retrospective 14 C birth dating of cells, it has been possible to demonstrate that the human heart retains a significant degree of myocyte regeneration throughout life and in the presence of chronic heart failure. Although the ability to regenerate cardiomyocytes and vascular structures cannot prevent the manifestations of myocardial aging or oppose the negative effects of ischemic and idiopathic dilated cardiomyopathy, understanding the complex mechanisms of tissue repair may identify novel strategies for the management of chronic heart failure and prolong health span and lifespan in the elderly. See p 1869.
Homeostatic and Tissue Reparation Defaults in Mice Carrying Selective Genetic Invalidation of CXCL12/Proteoglycan Interactions
CXCL12 regulates with unchallenged capacity both the tissue homing and survival of circulating tissue-specific progenitors, hematopoietic cells, and bone marrow stem cells and triggers inflammatory cell infiltration. Beyond the binding to its cognate receptor CXCR4, we speculate that the interaction of CXCL12 with proteoglycans, particularly heparan sulfate, enables the formation of chemokine gradients that determine the orientated migration and tissue recruitment of circulating cells. We engineered a mouse carrying a Cxcl12 gene (Cxcl12 Gagtm ) mutation that precludes interactions with heparan sulfate structures while not affecting CXCR4-dependent cell signaling of CXCL12 isoforms. After induced acute ischemia, a marked impaired capacity to support revascularization was observed in Cxcl12
Gagtm/Gagtm animals associated with a reduced number of infiltrating cells in the ischemic tissue. Of interest, Cxcl12␥ was the most abundant isoform in both the normal and ischemic muscle. Importantly, exogenous administration of CXCL12␥, which binds heparan sulfate with the highest affinity ever reported for a cytokine, fully restored vascular growth, whereas heparan sulfate-binding CXCL12␥ mutants failed to promote revascularization in Cxcl12
Gagtm/Gagtm animals. In terms of the potential of CXCL12 in regenerative medicine, the continuous delivery or administration in an immobilized form of CXCL12␣ is required to provide therapeutic effect in postischemic treatment. CXCL12␥ could overcome this limitation, thus efficiently activating the proangiogenic mechanisms. The findings presented here pave the way for investigating the contribution of CXCL12/heparan sulfate interactions to other homeostatic and physiopathological functions played by this unique chemokine and could eventually have broad relevance for other chemokine systems. See p 1882.
Effect of 9p21.3 Coronary Artery Disease Locus Neighboring Genes on Atherosclerosis in Mice
Atherosclerotic coronary artery disease (CAD) is the leading cause of death in the developed world. Epidemiological data show that environmental and genetic factors have roughly equal weight in determining the susceptibility to CAD and the rate of disease progression, although the genes that control this variability are not well characterized. Recently, large genome-wide association studies have identified Ͼ30 CAD risk loci. Some of the CAD risk loci work through known CAD risk factors such as lipids; however, this is not true for the majority of loci. This study systematically dissects the highly replicated 9p21.3 locus using different knock-out mice models of the neighboring genes, including CDKN2A, CDKN2B, and MTAP. We describe the complex molecular regulation within the region and show that MTAP affects the progression of atherosclerosis through several potential mechanisms including lymphocyte activation, and changes in metabolic and methylation profiles. This study is one of the first to show a change in atherosclerosis phenotype independent of lipids in a mice model generated as a follow-up of new locus identified from genome-wide association studies. This discovery suggests a novel pathway for atherosclerosis and hence opens the door to develop new markers of predicting the risk of atherosclerosis at the genomic, epigenomic, and metabolomic levels, and eventually new strategies for primary and secondary prevention of coronary artery disease. See p 1896.
Role of BMPR2 Alternative Splicing in Heritable Pulmonary Arterial Hypertension Penetrance
One of the most perplexing features of heritable pulmonary arterial hypertension is its reduced penetrance. Nearly 80% of mutation carriers have no clinical symptoms, but they can produce offspring who are affected by heritable pulmonary arterial hypertension. Thus, disease development cannot be predicted in a mutation carrier, creating anxiety in the patient and uncertainty about treatment in the physician. The data presented in this article point to a novel explanation for the reduced penetrance seen in heritable pulmonary arterial hypertension. Our data show that BMPR2 alternative splicing plays a role in this reduced penetrance. BMPR2 mutation carriers were more likely to have pulmonary arterial hypertension if they had higher levels of an alternatively spliced BMPR2 transcript, isoform-B, relative to the full-length BMPR2 transcript. Thus, our data suggest that although a BMPR2 mutation creates baseline susceptibility, an important determinant of disease penetrance appears to be the higher relative expression of the alternative spliced BMPR2 isoform-B. These data emphasize the importance of BMPR2 alternative splicing in heritable pulmonary arterial hypertension and raise an intriguing question: Can a predictive model of disease based on expression levels of the BMPR2 alternative splicing be developed? This predictive model will have obvious clinical utility in predicting which mutation carriers may eventually develop disease and thus will require appropriate follow-up. Because splicing can be manipulated in vivo by drugs, our findings suggest that manipulation of BMPR2 alternative splicing should be explored as a potential new intervention in heritable pulmonary arterial hypertension. See p 1907.
